A Phase II study of intratumoral injection of interleukin-12 plasmid and in vivo electroporation in patients with Merkel cell carcinoma

Trial Profile

A Phase II study of intratumoral injection of interleukin-12 plasmid and in vivo electroporation in patients with Merkel cell carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Tavokinogene telsaplasmid (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Sponsors OncoSec Medical
  • Most Recent Events

    • 24 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 02 Mar 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
    • 27 Sep 2015 According to an OncoSec Medical media release, results from this trial were presented at the 2015 European Cancer Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top